PFE · NRIX 10-KJan 28 '26
“Under the terms of the Pfizer Agreement, we received an upfront payment of $60.0 million.”
SNY 20-FFeb 17 '26
“Nurix Therapeutics (2020): collaboration to develop novel targeted protein degradation therapies;”
PFE · NVAX 10-KFeb 26 '26
“In January 2026, we entered into a License and Option Agreement with Pfizer Inc. ("Pfizer") for use of our Matrix-M™.”
SNY 20-FFeb 17 '26
“C o-exclusive licensing agreement with Novavax. The terms of the agreement include (i) a co-exclusive license to co- commercialize Novavax's current stand-alone adjuvanted COVID-19 vaccine worldwide (except in countries with existing Advance Purchase Agreements and in India, Japan, and South Korea, where Novavax has existing partnership agreements); (ii) a sole license to Novavax's adjuvanted COVID-19 vaccine for use in combination with Sanofi's flu vaccines; and (iii) a non- exclusive license to use the Matrix-M adjuvant in vaccine products. Novavax received an upfront payment of $ 500 million and could receive up to $ 700 million contingent on attainment of development, regulatory and commercialization milestones, representing up to $1.2 billion in total.”